Mark Steven Cohen MD

Associate Professor, Surgery
Specialties: 
Surgery

Locations

U of M General Surgery

Taubman Center Floor 2 Reception C
1500 E Medical Center Dr SPC 5332
Ann Arbor
MI
48109
Phone:
734-936-5738
Fax:
734-936-6927

Credentials

Medical School or Training

  • Washington University School of Medicine, 1998

Residency

  • Washington University School of Medicine, Surgery General, MO, 2006

Fellowship

  • Oncology/Endocrinology, Washington University School of Medicine, 2003

Board Certification

  • Surgery

Biography

Dr. Cohen is currently Associate Professor of Surgery and Director of Endocrine Surgery Research. He received his medical degree in 1998 from Washington University School of Medicine in St. Louis and completed his general surgery residency as well as a NIH sponsored fellowship in endocrine and oncologic surgery at Barnes-Jewish Hospital. Before coming to the University of Michigan in 2012, he was Associate Professor of Surgery and Pharmacology and Vice-Chair for Research in the Department of Surgery at the University of Kansas.

His clinical interests include endocrine surgery specifically thyroid surgery for benign and malignant disease, minimally invasive parathyroid surgery and adrenalectomy, as well as surgery for advanced melanomas including hyperthermic isolated limb perfusion. He is Boarded by the American Board of Surgery and is a Fellow of the American College of Surgeons.

In addition to his clinical interests, Dr. Cohen has an active basic science and translational research laboratory on the NCRC campus focused on translational targeted cancer-drug development and drug delivery systems in thyroid cancer, head and neck squamous cell cancer, melanoma and breast cancer. Specifically his research includes development of a patented nanocarrier based drug-delivery platform which improves cancer drug delivery to tumors and their draining lymph nodes for enhanced efficacy while decreasing the systemic toxicity of the drugs. Additionally his lab is translating novel natural product withanolides and novel c-terminal HSP-90 inhibitors into improved anti-cancer drugs for future clinical trials in thyroid cancer, head and neck squamous cell cancer, breast cancer, melanoma and adrenal cancer. His research funding includes the Susan G. Komen Foundation, the American Cancer Society, and the National Institute of Health.